LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study

J. Cortés; S-B. Kim; W-P. Chung; S-A. Im; Y.h. Park; R. Hegg; M.h. Kim; L-M. Tseng; V. Petry; C-F. Chung; H. Iwata; E. Hamilton; G. Curigliano; B. Xu; C. Lee; Y. Liu; J. Cathcart; E. Bako; S. Verma; S.a. Hurvitz

doi:10.1016/j.annonc.2021.08.2087

LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study

J. Cortés, S-B. Kim, W-P. Chung, S-A. Im, Y.h. Park, R. Hegg, M.h. Kim, L-M. Tseng, V. Petry, C-F. Chung, H. Iwata, E. Hamilton, G. Curigliano, B. Xu, C. Lee, Y. Liu, J. Cathcart, E. Bako, S. Verma, S.a. Hurvitz

Department of Internal Medicine(NCKUH)

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	S1287-S1288
Journal	Annals of Oncology
Volume	32
DOIs	https://doi.org/10.1016/j.annonc.2021.08.2087
Publication status	Published - 2021 Sept 1

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.annonc.2021.08.2087

https://linkinghub.elsevier.com/retrieve/pii/S092375342104391X

Cite this

Cortés, J., Kim, S.-B., Chung, W.-P., Im, S.-A., Park, Y. H., Hegg, R., Kim, M. H., Tseng, L.-M., Petry, V., Chung, C.-F., Iwata, H., Hamilton, E., Curigliano, G., Xu, B., Lee, C., Liu, Y., Cathcart, J., Bako, E., Verma, S., & Hurvitz, S. A. (2021). LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study. Annals of Oncology, 32, S1287-S1288. https://doi.org/10.1016/j.annonc.2021.08.2087

@article{3539c09fec834d21ac7b616f8fbdab5e,

title = "LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study",

author = "J. Cort{\'e}s and S-B. Kim and W-P. Chung and S-A. Im and Y.h. Park and R. Hegg and M.h. Kim and L-M. Tseng and V. Petry and C-F. Chung and H. Iwata and E. Hamilton and G. Curigliano and B. Xu and C. Lee and Y. Liu and J. Cathcart and E. Bako and S. Verma and S.a. Hurvitz",

year = "2021",

month = sep,

day = "1",

doi = "10.1016/j.annonc.2021.08.2087",

language = "English",

volume = "32",

pages = "S1287--S1288",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Cortés, J, Kim, S-B, Chung, W-P, Im, S-A, Park, YH, Hegg, R, Kim, MH, Tseng, L-M, Petry, V, Chung, C-F, Iwata, H, Hamilton, E, Curigliano, G, Xu, B, Lee, C, Liu, Y, Cathcart, J, Bako, E, Verma, S & Hurvitz, SA 2021, 'LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study', Annals of Oncology, vol. 32, pp. S1287-S1288. https://doi.org/10.1016/j.annonc.2021.08.2087

TY - JOUR

T1 - LBA1 Trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (Pts) with HER2+ metastatic breast cancer (mBC): Results of the randomized phase III DESTINY-Breast03 study

AU - Cortés, J.

AU - Kim, S-B.

AU - Chung, W-P.

AU - Im, S-A.

AU - Park, Y.h.

AU - Hegg, R.

AU - Kim, M.h.

AU - Tseng, L-M.

AU - Petry, V.

AU - Chung, C-F.

AU - Iwata, H.

AU - Hamilton, E.

AU - Curigliano, G.

AU - Xu, B.

AU - Lee, C.

AU - Liu, Y.

AU - Cathcart, J.

AU - Bako, E.

AU - Verma, S.

AU - Hurvitz, S.a.

PY - 2021/9/1

Y1 - 2021/9/1

U2 - 10.1016/j.annonc.2021.08.2087

DO - 10.1016/j.annonc.2021.08.2087

M3 - Article

SN - 0923-7534

VL - 32

SP - S1287-S1288

JO - Annals of Oncology

JF - Annals of Oncology

ER -